The inventors of the present invention suggested, in PTL 2, an anti-cancer agent which does not use a carrier. PTL 2 discloses a compound in which a drug is made to bind to a metal-salen complex compound. Since the compound disclosed in PTL 2 is self-magnetic, the carrier is not required in order to carry the drug. However, there is a demand for an anti-cancer agent which has less side effects and whose cancer cell killing effect is further enhanced. Particularly, an anti-cancer agent which exhibits the excellent effect of killing cancer cells of triple-negative breast cancer has not been discovered. The anti-cancer agent which continuously kills the cancer cells is being examined from the viewpoint of enhancement of the killing effect.

CITATION LIST

PATENT LITERATURE

[0005]

PTL 1: Japanese Patent Application Laid-Open (Kokai) Publication No. 2001-010978


PTL 2: Japanese Patent Application Laid-Open (Kokai) Publication No. 2012-167067

SUMMARY

[0005a]

In one aspect, there is provided use of an anti-cancer agent containing

a complex represented by Formula (3)



(3)

,

produced by making a metal-salen complex compound, which includes a central metal and N, N, O, O as a quadridentate ligand and is magnetic, the

metal-salen complex compound binding to a paclitaxel molecule which is anticancerous,

in the manufacture of a medicament to kill cancer cells,

wherein the cancer cells are cancer cells of breast cancer or triple-negative breast cancer.

PROBLEMS TO BE SOLVED BY THE INVENTION

[0006]

It is an object of the present invention to provide an anti-cancer agent capable of continuously killing cancer cells. It is an object of the invention to provide an anti-cancer agent for killing cancer cells of breast cancer, particularly, cancer cells of triple-negative breast cancer.

MEANS FOR SOLVING THE PROBLEMS

[0007]


The present invention is an anticancer agent containing a complex produced by making a metal-salen complex compound, which includes a central metal and (N, N, O, O) as a quadridentate ligand and is magnetic, bind to taxane molecules which are anticancerous, and the anticancer agent is to kill cancer cells regarding which phase transition occurs between phases including Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis. The present invention is an anti-cancer agent suited for

CLAIMS

[Claim 1]

Use of an anti-cancer agent containing

a complex represented by Formula (3)



(3)

produced by making a metal-salen complex compound, which includes a central metal and N, N, O, O as a quadridentate ligand and is magnetic, the metal-salen complex compound binding to a paclitaxel molecule which is anticancerous,

in the manufacture of a medicament to kill cancer cells,

wherein the cancer cells are cancer cells of breast cancer or triple-negative breast cancer.

[Claim 2]

The use according to claim 1, wherein the anti-cancer agent is made to be indwelled in cancer cells constituting affected site tissues by applying an external magnetic field to the affected site tissues.